铁螯合剂对骨血管形成的影响

Effect of iron chelators on the angiogenesis of bone

人体本身排泄铁的能力有限,铁螯合剂可与体内铁结合有效地提高铁的排泄,从而降低体内铁负载及其在各器官内的异常沉积。早期铁螯合剂主要用于反复输血患者及地中海贫血等铁超载性疾病,但近期研究显示,其还具有抗氧化应激损伤、抗缺血再灌注损伤、抗铁过载骨质疏松及改善组织血供等特性,同时血管形成在骨质疏松中的作用越来越重视,本文就近年来铁螯合剂对血管形成的影响及其在骨质疏松中的相关研究进行综述。

The body itself owns a limited ability to excrete iron. Iron chelators can be combined with body iron effectively, and then increases iron excretion, thereby reducing the load of too much iron in the body and the abnormal deposition in various organs. Early iron chelator is mainly used for repeated blood transfusions in patients with thalassemia and iron overload diseases, but recent studies have shown that it has anti-oxidative stress, anti-iscbemie repeffusion injury, anti-osteoporosis and improve tissue blood supply. Meantimes vessels is more important in the field of osteoporosis. This paper reviews the research of iron chelators in the formation of blood vessels and field of osteoporosis in recent years.